Kazushige Ishida

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Metastatic Breast Cancer

Epidermal Growth Factor Receptor

Placebo Controlled

Top Venues

Breast cancer research and treatment

Breast cancer (Tokyo, Japan)

This page only lists publications with an associated author ORCID identifier.

Publications

Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Kazushige Ishida, Koji Ohnuki, Shin Usami, Hideaki Komatsu, Akira Sasaki
A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Japan. Breast cancer (Tokyo, Japan) 28 (1) (2020)